Principal Financial Group Inc. Trims Holdings in Moderna, Inc. (NASDAQ:MRNA)

Principal Financial Group Inc. decreased its holdings in Moderna, Inc. (NASDAQ:MRNA) by 1.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 373,484 shares of the company’s stock after selling 5,967 shares during the quarter. Principal Financial Group Inc. owned about 0.10% of Moderna worth $15,529,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of MRNA. Wilmington Savings Fund Society FSB raised its position in Moderna by 295.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after purchasing an additional 587 shares during the last quarter. MassMutual Private Wealth & Trust FSB raised its position in Moderna by 58.2% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after buying an additional 389 shares during the last quarter. Blue Trust Inc. raised its position in Moderna by 53.1% during the 4th quarter. Blue Trust Inc. now owns 1,119 shares of the company’s stock worth $47,000 after buying an additional 388 shares during the last quarter. EMC Capital Management raised its position in Moderna by 311.2% during the 4th quarter. EMC Capital Management now owns 1,250 shares of the company’s stock worth $52,000 after buying an additional 946 shares during the last quarter. Finally, Larson Financial Group LLC raised its position in Moderna by 53.5% during the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock worth $61,000 after buying an additional 317 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Insiders Place Their Bets

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the firm’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the sale, the insider now directly owns 19,717 shares of the company’s stock, valued at $843,690.43. This trade represents a 6.71 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 2,664 shares of company stock valued at $115,210 in the last ninety days. Insiders own 15.20% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Hsbc Global Res upgraded shares of Moderna from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 18th. Bank of America cut their price objective on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a research report on Tuesday, February 11th. Wolfe Research assumed coverage on shares of Moderna in a research report on Friday, November 15th. They set an “underperform” rating and a $40.00 price objective for the company. Morgan Stanley cut their price target on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a report on Wednesday, January 15th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and issued a $40.00 price target on shares of Moderna in a report on Tuesday, February 18th. Four investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Moderna has a consensus rating of “Hold” and a consensus price target of $60.63.

Moderna Trading Down 2.0 %

Shares of NASDAQ MRNA opened at $33.22 on Wednesday. Moderna, Inc. has a 52 week low of $29.25 and a 52 week high of $170.47. The stock has a market cap of $12.78 billion, a price-to-earnings ratio of -3.58 and a beta of 1.59. The company’s 50-day moving average price is $37.89 and its 200 day moving average price is $52.10.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.